ACUTE MYELOID LEUKEMIA

This study gives venetoclax to 165 people with blood cancers like leukemia and lymphoma who already benefited from the drug in earlier studies. The main goal is to track side effects and see how safe the drug is over a longer period. Participants must have tolerated the drug well…

This study tests whether a combination of two chemotherapy drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) from returning in patients who are already in remission. About 50 adults whose leukemia is in first remission but who are not ready for a stem …

This early-phase trial tests a new drug (navtemadlin) combined with two standard drugs (decitabine and venetoclax) in adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to find the safest dose and check for side effects. About …

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in adults whose cancer has returned or not responded to prior treatment, as well as in older adults newly diagnosed who cannot tolerate strong chemotherapy. About 85 participa…

This study compares two types of stem cell donors for children, teens, and young adults with high-risk leukemia or myelodysplastic syndrome (MDS). Participants receive a stem cell transplant from either a partially matched family donor or a fully matched unrelated donor. The goal…

This study tests a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is either related to prior cancer treatment or developed from other blood disorders. The goal is to fin…

This study tests whether adding the drug venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The main goals are to see if the combination helps clear cancer cells from the bone m…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study tests whether two drugs, venetoclax and azacitidine, can help prevent leukemia from returning in 100 adults who have already had a stem cell transplant. Participants have high-risk acute myeloid leukemia or related blood cancers and are in remission after transplant. T…

This program offers early access to the investigational drug ABBV-787 for people with acute myeloid leukemia who have no other treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by re…

This early-stage trial tests a new drug called ziftomenib (KO-539) in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or control the cancer…

This early-phase trial tests whether a single infusion of specially grown donor immune cells (γδ T-cells) can prevent acute myeloid leukemia from returning in 20 patients who are at high risk of relapse after a stem cell transplant. The study aims to find the safest dose and meas…

This study follows about 100 adults with acute myeloid leukemia (AML) in Israel who are already prescribed venetoclax by their doctor. Researchers will track how long patients live and how many achieve remission, without giving any new treatments. The goal is to see how well the …

This study tests a new way to grow stem cells from umbilical cord blood to help people with high-risk blood cancers like leukemia and lymphoma recover faster after a bone marrow transplant. About 22 patients will receive the expanded stem cells along with standard chemotherapy an…

This study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to gather long-term safety information. About …

This study tested whether adding the drug veliparib to standard chemotherapy helps people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults took part. The goal was to see if the combination improved response …

This study compares two chemotherapy regimens for adults aged 60-75 newly diagnosed with acute myeloid leukemia (AML) who can tolerate intensive treatment. About 90 participants will be randomly assigned to one of three groups to see which approach leads to better event-free surv…

This early-stage trial tests a new drug called DR-18 in 20 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or persists after a stem cell transplant. DR-18 is designed to boost the body's immune system to fight the cancer. The main goals a…

This early-phase study tests a drug called tomivosertib in 15 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill daily for 28-day c…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests whether adding a precise, high-dose radiation to the marrow (total marrow irradiation) to standard chemotherapy before a donor stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) live longer without …

This early-phase study tests a new daily pill called BMF-500 in adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (FLT3 mutation) found in some leukemias. The main goals are to check safety, find …

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers like leukemia and lymphoma. The goal was to see if this approach could help patients survive and recover without severe side effects.…

This study tests whether adding a drug called uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer without the cancer returning. About 267 participants will receive either chemo alone or chemo plus uproleselan. The goal is to see i…

This study tests whether a combination of two drugs, venetoclax and azacitidine, works as well as or better than standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML). About 172 participants will be randomly assigned to receive either the new combo or…

This early-stage study tests the safety of adding venetoclax to a standard chemotherapy drug, decitabine, for people with acute myeloid leukemia (AML) that is hard to treat. About 26 adults with high-risk AML will take part. The goal is to find the best dose and see how well the …

This early-phase trial tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a stem cell transplant. The treatment combines a special donor cell infusion with an immunotherapy drug (ipilimumab) to fight the cancer. The main goal is to find the s…

This early-stage trial tests a new drug (8-chloro-adenosine) combined with an existing drug (venetoclax) in 30 adults whose acute myeloid leukemia has come back or stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects. The …

This early-phase trial tests a new way to prepare adults with acute myeloid leukemia (AML) for a donor stem cell transplant. Instead of full-body radiation, it uses targeted radiation to the bone marrow and lymph nodes, followed by a drug called cyclophosphamide to prevent graft-…

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

This early-phase study tests a new therapy using donor immune cells trained to recognize four proteins found on AML and MDS cancer cells. The cells are given to patients at least 30 days after a stem cell transplant. The main goal is to find the safest dose and see if the cells c…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that controls the disease. Sixteen adults aged 18 and older are …

This early-phase study tests a new targeted therapy called PVEK, which delivers chemotherapy directly to cancer cells, combined with a standard chemo regimen (FLAG-Ida) for adults with newly diagnosed high-risk acute myeloid leukemia (AML) and other aggressive blood cancers. The …

This study tests a new all-oral treatment (ASTX727 plus venetoclax) against standard IV chemotherapy for younger adults (18-65) with high-risk acute myeloid leukemia (AML) that lacks a FLT3 mutation. The goal is to see if the pill combo is safer and works as well or better. Only …

This study is for people newly diagnosed with a specific type of acute myeloid leukemia (AML) linked to prior cancer treatment or other bone marrow disorders. It tests whether adding the drug pomalidomide to standard chemotherapy can improve treatment results. About 50 adults wil…

This study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new way to prepare the body for a donor stem cell transplant by combining targeted radiation (TMLI) with two chemotherapy drugs. The goal is to find the safest dose that can kill …

This study tests whether giving a drug that affects gene activity (epigenetic priming) before standard chemotherapy is safe and effective for children with newly diagnosed acute myeloid leukemia (AML). About 206 participants will receive either azacitidine or decitabine for five …

This study tests two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant for people with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen helps patients live longer without the…

This study tests an experimental drug called quizartinib, given with chemotherapy, for children and young adults (ages 1 month to 21 years) whose acute myeloid leukemia (AML) has come back or not responded to treatment. The goal is to see if the combination can safely help achiev…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special stem cell transplant designed to reduce serious side effects like graft-versus-host disease. The trial compares Orca-T to standard stem cell transplants in 187…

This study tests a new radiation technique called total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant from a half-matched donor. The goal is to deliver higher radiation to cancer cells while protecting healthy organs, potentially reducing serious side…

This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (azacitidine and venetoclax) helps older adults with newly diagnosed acute myeloid leukemia (AML) achieve deeper remissions and lower the chance of the cancer returning. About 60 participan…

This study tests whether adding the drug selinexor to standard chemotherapy can help children with a rare, high-risk form of acute myeloid leukemia (AML) called NUP98-positive. The trial will enroll 10 children and measure how many achieve complete remission. The goal is to impro…

This study tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 116 adults aged 18 to 70 with …

This study tests a new treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in the lab to recognize and attack AML cells carrying a protein call…

This early-stage study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatment. The therapy uses a patient's own or donor's immune cells that are genetically modified to recognize and attack cancer cells carry…

This study gives a small group of adults with acute myeloid leukemia (AML) continued access to an oral form of the chemotherapy drug azacitidine. All 20 participants had already completed a previous bioequivalence study of the same tablet. The main goal is to track any side effec…

This study tested a bone marrow transplant using frozen, banked bone marrow from unrelated donors for people with blood cancers like leukemia. The goal was to see if it safely restores healthy blood cells and controls the disease. The trial was withdrawn before enrolling any part…

This study tests a new drug called bexmarilimab combined with standard treatments for people with certain blood cancers (MDS, CMML, or AML). The goal is to find a safe dose and see if the combination helps control the disease. About 181 adults will take part, and the study is cur…

This study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can improve survival in adults with acute myeloid leukemia who are not healthy enough for standard intensive treatment. About 60 participants will be randomly assigned to on…

This study tests a specially engineered donor graft (Orca-Q) in children and young adults with certain blood cancers who need a stem cell transplant. The goal is to see if this processed graft is safe and helps the new cells take hold. About 40 participants will be enrolled.

This large phase 3 trial tests whether adding bortezomib and sorafenib to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) live longer without the cancer returning. The study includes over 1,600 participants and focuses on those with a specific…

This study tests whether the drug ruxolitinib can help prevent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) from coming back after a stem cell transplant. It includes older adults whose cancer is in remission. The goal is to improve survival and reduce complicat…

This study tests whether adding a drug called decitabine to standard chemotherapy can improve remission rates in adults with acute myeloid leukemia (AML) that is harder to treat. About 178 participants will receive either low or high dose decitabine alongside chemo drugs daunorub…

This study tests a drug called olaparib in 14 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to treatment, and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to g…

This study tests a new drug called sonrotoclax combined with strong chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combo is safe and helps more patients achieve remission. Treatment is adjusted based on each person's genetic…

This study tests whether a new drug called galinpepimut-S (GPS) can help adults with acute myeloid leukemia (AML) stay in remission longer after their second round of treatment. About 127 participants will receive either GPS or the doctor's choice of standard therapy. The main go…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease. About 313 adults with various blood cancers…

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) whose cancer did not respond to standard treatments. The goal is to see if the drug can improve blood cell counts and control the di…

This study tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) specially trained immune cells (memory-like NK cells) after a half-matched donor stem cell transplant can keep the cancer away longer. About 60 adults whose leukemia did not respond to standa…

This early-stage trial tests the safety of combining two drugs, RAD001 and PKC412, in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to standard treatments. The goal is to find the highest safe dose of RAD001 when giv…

This early-phase study tests the safety and best dose of combining bortezomib, sorafenib, and decitabine for adults with acute myeloid leukemia (AML). It includes older patients who cannot have standard treatment or those whose leukemia has returned. The goal is to find a tolerab…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve deeper remission. About 49 adults with AML, including those whose cancer arose from prior conditions, will receive …

This study tests whether the immunotherapy drug nivolumab can eliminate leftover cancer cells and prevent relapse in adults with acute myeloid leukemia (AML) who are in remission after chemotherapy. About 82 participants will receive either nivolumab or standard care. The goal is…

This program gives patients with blood cancers like leukemia or myelodysplastic syndrome access to Orca-T, a cell therapy, when the commercial version made for them doesn't meet quality standards. The goal is to provide treatment when no other option is available. Participants ar…

This study checks the long-term safety of the drug ruxolitinib (given alone or with panobinostat) in people with certain blood or immune conditions like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already b…

This early-phase trial studies the safety and best dose of navtemadlin when added to standard chemotherapy (cytarabine and idarubicin) for people with newly diagnosed acute myeloid leukemia (AML). Navtemadlin blocks a protein that helps cancer cells grow. The goal is to see if th…

This study tests a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 people with Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia that has worsened. The goal is to see how well the drugs work together to control the ca…

This early-phase study tests a new type of CAR T-cell therapy made from donor cells (WU-CART-007) for people with CD7-positive blood cancers, including acute myeloid leukemia and T-cell lymphoma that have not responded to standard treatments. The therapy is designed to target and…

This study is testing a combination of two drugs, ASTX727 and venetoclax, in adults with acute myeloid leukemia (AML) who are 75 or older or have health issues that make standard strong chemotherapy too risky. The goal is to see if the combination is safe and effective at control…

This study tests whether an oral chemotherapy drug (azacitidine) can help keep acute myeloid leukemia (AML) from returning in Japanese patients aged 55 and older who are already in remission. Participants receive either the drug or a placebo along with standard supportive care. T…

This study was designed to test the safety and best dose of a drug called revumenib in children with certain types of leukemia after they had a stem cell transplant. The goal was to see if revumenib could help prevent the cancer from returning. However, the trial was withdrawn be…

This early-stage study tests a new approach for people with acute myeloid leukemia (AML) that has returned or is likely to return, and who cannot have a bone marrow transplant. Researchers take the patient's own leukemia cells, modify them in the lab to produce a protein called I…

This early-phase study tests a new drug called CRD3874-SI in 6 adults with acute myeloid leukemia that has returned or not responded to standard treatment. The drug activates a protein called STING, which helps the immune system recognize and kill cancer cells. The main goals are…

This study tests a combination of three drugs (chidamide, azacytidine, and a chemotherapy regimen called HAG) in adults aged 18 to 70 with acute myeloid leukemia that has come back or not responded to standard treatment. The goal is to see if this combination can shrink or elimin…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see if the combination could safely lead to complete remission (no signs of cancer) and improve surviv…

This early-stage trial is testing a new drug combination for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The treatment combines a targeted radiation therapy (lintuzumab-Ac-225) with two other drugs (venetoclax and ASTX-727) t…

This early-stage trial tests whether adding a new drug called iadademstat to two standard chemotherapy drugs (venetoclax and azacitidine) is safe and tolerable for adults with untreated acute myeloid leukemia (AML). The study enrolls 45 people with intermediate- or high-risk AML.…

This early-phase study tests whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for people newly diagnosed with acute myeloid leukemia (AML). About 50 adults will receive the combination during initial treatment and follow-up cycles. The goal is to …

This early-stage trial tests a combination of two drugs—entrectinib and ASTX727—in adults with acute myeloid leukemia (AML) that has returned or not responded to treatment and has a specific genetic change (TP53 mutation). The goal is to find the safest dose and see if the combin…

This study follows about 200 adults in Canada with acute myeloid leukemia (AML) who cannot receive intensive chemotherapy. All participants take venetoclax pills daily as part of their routine care. Researchers track survival and remission rates over 36 months to see how well the…

This study looks at whether adding a palliative care team to standard leukemia treatment helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life care. About 320 patients receiving non-intensive therapy will take par…

This study looks at whether cognitive behavioral therapy (CBT) can help people with acute myeloid leukemia (AML) or lymphoma who feel very tired from their cancer or treatment. About 48 patients will take part in up to 7 counseling sessions to learn new ways to cope with fatigue.…

This study looks at whether training parents in specific skills can improve learning and school functioning for Latino children with acute leukemia or lymphoma. About 214 families will take part, with some parents receiving a high-intensity program and others getting standard sup…

This study looks at whether checking for leukemia-related gene mutations after initial treatment can help predict which patients will stay cancer-free. About 107 adults aged 18-60 with intermediate-risk acute myeloid leukemia (AML) are being followed. The goal is to see if those …

This early-phase study is looking at how the immune system responds to leukemia tumors after low-dose radiation. Ten adults with new or returning acute myeloid leukemia will have their immune responses measured. The goal is to learn if adding immunotherapy could help future patie…

This study tests whether a high-intensity digital health program—including video coaching and a special website—can help children aged 6 to 12 who were treated for leukemia or lymphoma improve their learning and school performance. Many children with these cancers are cured, but …

This early-phase trial is testing whether atorvastatin, a widely used cholesterol medication, can reduce levels of a faulty protein called p53 in people with various cancers, including solid tumors and acute myeloid leukemia. About 50 participants will take the drug for 1 to 4 we…

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict complications like infections, relapse, or survival. The goal is to better understand the role of muscle strength at k…

This study looks at whether a lab test can predict how well chemotherapy will work for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Researchers will take blood samples before treatment and test them in the lab to see if the results match how patien…

This study looks at how a protein called adrenomedullin helps leukemia cells grow and spread in the bone marrow. Researchers will collect blood and bone marrow samples from 72 adults newly diagnosed with acute myeloid leukemia (AML). They will measure protein levels and run lab t…

This study follows 500 adults aged 18-65 who finished chemotherapy for certain cancers and are in remission. Over 5 years, researchers will check for 19 possible late side effects like heart problems, memory issues, and fatigue. The goal is to catch these problems early and impro…

This study looks at whether adults with newly diagnosed acute myeloid leukemia (AML) can safely skip an immediate second round of chemotherapy based on results from a standard mid-induction bone marrow biopsy. Researchers will track how many patients achieve complete remission wi…

This study is testing a new blood test called AlloHeme that looks at DNA to see if a patient's own cells are coming back after a bone marrow transplant. The goal is to find out if this test can predict a relapse of leukemia or myelodysplastic syndrome earlier than current methods…

This study looks at how different treatments affect the quality of life of people aged 60 and older who are newly diagnosed with acute myeloid leukemia (AML). Researchers will track patients' well-being using a detailed questionnaire to learn what matters most to them. The goal i…

This study tests whether a special PET scan using a radioactive tracer called FLT can measure how well chemotherapy is working in adults with newly diagnosed acute myeloid leukemia (AML). The scan lights up fast-growing cancer cells, and researchers want to see if it can predict …

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…

This study looks at how common acquired pyruvate kinase deficiency is in people with certain blood cancers or pre-cancer conditions. Researchers will take a single blood sample from 100 participants to check for low enzyme activity or gene changes. The goal is to better understan…